inactivated vaccine to prevent progressive and non-progressive atrophic rhinitis in pigs

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 07/12/2018

Authorisation details

Product details
Agency product number
Active substance
  • inactivated Bordetella bronchiseptica, strain 833CER
  • recombinant type-D Pasteurella-multocida toxin
International non-proprietary name (INN) or common name
inactivated vaccine to prevent progressive and non-progressive atrophic rhinitis in pigs
Pigs (gilts and sows)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Laboratorios Hipra S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Avda. La Selva, 135
17170- Amer (Girona)

Product information

09/11/2018 Rhiniseng - EMEA/V/C/000160 - IB/0008

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella-bronchiseptica and Pasteurella-multocida infections during the fattening period.

Challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

Assessment history

How useful was this page?

Add your rating